August 21, 2017 / 7:37 PM / a year ago

BRIEF-ALK to accelerate launches of Odactra in U.S.

Aug 21 (Reuters) - Alk-Abello A/S:

* Says ‍FDA transferred U.S. product licences for slit-tablet portfolio to ALK

* Says ‍ALK plans to expand pivotal phase III clinical trial on allergic asthma to include U.S. patients based on discussions with FDA​

* Says FY guidance for operating profit (EBITDA) revised due to accelerated investments to support earlier launches of HDM-SLIT tablet in USA,CANADA​

* Says ‍will bring forward North American launches of house dust mite SLIT-tablet from mid-2018 to Q4 2017​

* Says ‍FY EBITDA is now expected to be approximately DKK 225-250 million​

* Says ‍full-year revenue is still projected at DKK 2.8-3.0 billion​

* Says ‍full year free cash flow is now expected at approximately minus DKK 700 million​ Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below